Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivolcizumab plus TAS-102 for third-line metastatic colorectal cancer
ChiCTR2400091500Phase 2Not yet recruiting
- Sponsor
- Hebei General Hospital
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab and trifluridine + tipiracil in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Hebei General Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
ivonescimabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400091500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091500.